A study that analyzed the long-term safety and effectiveness of trastuzumab - more commonly known as Herceptin - found it significantly improves long-term survival of patients with HER-2 positive breast cancer when combined with chemotherapy.

The study, published in the Journal of Clinical Oncology, analyzed data from two independent trials designed to examine overall survival of patients with early-stage HER2-positive breast cancer who received chemotherapy with and without Herceptin.